

FOR IMMEDIATE RELEASE

Contact: Lescarden Inc.  
212-687-1050

**LESCARDEN ENTERS INTO NEW DISTRIBUTION AGREEMENT**  
**FOR**  
**CATRIX® WOUND DRESSING IN SPAIN**

NEW YORK, N.Y. June 30, 2006

LESCARDEN INC. announced today that Smith & Nephew has entered into a semi-exclusive license agreement to distribute Lescarden's Catrix® Wound Dressing in Spain. Under this agreement Smith & Nephew will distribute Catrix to the hospital and primary care markets. Smith & Nephew's marketing and sales efforts will commence immediately.

Smith & Nephew is a global medical technology business, specializing in Orthopaedic Trauma & Clinical Therapies, Orthopaedic Reconstruction, Endoscopy and Advanced Wound Management products. Smith & Nephew is recognized as a leader in advanced wound management with an array of products and technologies for treating chronic wounds. The company has over 8,500 employees and operates in 33 countries around the world generating annual sales of \$2.6 billion in 2005. The Advanced Wound Care division accounted for approximately 27% of total sales.

Lescarden's President, William Luther, stated, "We at Lescarden are pleased to have Smith & Nephew as our distribution partner in Spain. Smith & Nephew's strong field sales presence, distribution and marketing expertise in Spain will improve our penetration in this key market."

Catrix Wound Dressing, approved by the FDA and throughout the European Union, is a topically applied powder derived from specially processed bovine tracheal cartilage. The Wound Dressing is indicated for the management of chronic skin wounds including decubitus (pressure) ulcers, venous stasis ulcers and diabetic ulcers as well as second- degree burns and post-radiation dermatitis.

Clinical studies performed by senior nursing professionals associated with the Spanish Ulcer and Chronic Wound Advisory Panel concluded that the product was "...effective in the treatment of pressure ulcers that did not heal after the application of one of several standard treatments...", and that "...these results prove that the treatment with Catrix significantly reduces

the treatment, and therefore leads to a reduction in the sanitary cost in this kind of patient..." It was calculated that the application of Catrix reduced the overall treatment cost for this type of chronic wound by 38%.

Lescarden, Inc. is a biotechnology company dedicated to the development of natural, biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. For more information please contact the Company at 212- 687-1050 or visit [www.catrix.com](http://www.catrix.com).